News
AI dominates China’s elite doctors in cancer diagnosis competition
A custom-built AI designed to diagnose brain tumors and predict hematoma expansion dominated some of China’s best doctors in a competition last Saturday in Beijing. The AI, dubbed BioMind, ultimately scored 2:0 against its human competitors, comprised of 15 senior doctors from China’s premier hospitals.
BioMind was developed by a collaboration between a team from the Artificial Intelligence Research Center for Neurological Disorders at the Beijing Tiantan Hospital and researchers from the Capital Medical University. BioMind’s developers opted to feed the AI with data sets featuring tens of thousands of images depicting nervous-system-related diseases, which were retrieved from Tiantan Hospital’s archives stretching over the past decade.
Wang Yongjun, executive vice-president of Tiantan Hospital, stated that this training ultimately enabled the AI to become proficient in diagnosing neurological diseases such as meningioma and glioma with an accuracy rate of over 90%. According to Wang, such rates are comparable to the accuracy of a senior doctor, according to a report from state-owned Xinhua News.
During its the competition on Saturday, BioMind was able to correctly diagnose brain tumors with an accuracy rate of 87% out of a total of 225 cases. The AI was also able to complete its task in 15 minutes. In comparison, the team of 15 elite doctors was able to achieve an accuracy rate of 66% when diagnosing brain tumors, finishing the task in 30 minutes. Apart from this, BioMind was able to make correct predictions in 83% of brain hematoma expansion cases, while its human competition displayed a more conservative 63% accuracy.
Despite the AI’s strong performance against China’s elite doctors on Saturday, however, Cheng Jingliang, a professor of radiology at the First Affiliated Hospital of Zhengzhou University, stated that artificial intelligence systems for the medical field are still well into their infancy. According to Cheng, AI is already being used in hospitals to help doctors read images such as lung scans, but when it comes to giving full diagnoses to patients, artificial intelligence still lags far behind that of senior medical professionals.
In a statement to China Daily, Paul Parizel from the Antwerp University Hospital in Belgium, who served as a member of the jury during last Saturday’s AI vs. human doctors competition, believes that systems such as BioMind would prove to be incredibly valuable when integrated to existing medical practices.
“It will be like a GPS guiding a car. It will make proposals to a doctor and help the doctor diagnose. But it will be the doctor who ultimately decides, as there are a number of factors that a machine cannot take into consideration, such as a patient’s state of health and family situation,” he said.
The United States initially led the artificial intelligence race, but over the years, China has steadily gained ground in the AI industry. Thanks to a population that is compliant to the application of new technologies, as well as a government that actively pushes AI researchers to push further, China is on track to overtake the United States in the near future. Last January alone, the Chinese government announced plans to build a $2.1 billion technopark in Beijing that is expected to house companies actively involved in AI research and development. The United States does not have a comparable initiative to date. This was confirmed by Jack Clark of Elon Musk-backed OpenAI, who previously stated that the country lacks a central national strategy on artificial intelligence.
“It is confusing that we have this technology of such obvious power and merit and we are not hearing full-throated support, including financial support,” Clark said.
Elon Musk
SpaceX’s newest logo confirms everything about what it’s become
SpaceX officially absorbed xAI under the SpaceXAI brand, completing the largest private merger in history.
SpaceX made its corporate transformation official in May 2026 when Elon Musk posted on X that xAI would cease to exist as a standalone company. “xAI will be dissolved as a separate company, so it will just be SpaceXAI, the AI products from SpaceX,” he wrote.
A new SpaceXAI logo was announced today, visually embedding the xAI letters inside the SpaceX identity, which can be seen as a deliberate design choice that signals the merger is not a partnership but a full absorption and XAi a core function of the same company. The same way Starlink is not a separate brand but a SpaceX product. The announcement closed the loop on a process that began February 2, 2026, when SpaceX acquired xAI in the largest private merger in history, valued at $1.25 trillion. SpaceX at $1 trillion and xAI at $250 billion.
We are now @SpaceXAI. pic.twitter.com/ema66xDWC9
— SpaceXAI (@SpaceXAI) July 6, 2026
The reason SpaceX bought xAI was stated plainly by Musk at the time of the deal: to build orbital data centers. SpaceX had simultaneously filed with the FCC to launch up to one million satellites designed to function as AI compute nodes in low Earth orbit, escaping what Musk described as the energy constraints limiting AI development on Earth.
xAI provided the AI software stack, with Grok, the X platform, and the Colossus supercomputer infrastructure in Memphis with over 220,000 NVIDIA GPUs, while SpaceX provided the rockets, Starlink, and the capital base to fund it. The two companies needed each other. xAI was burning $2.5 billion in losses on $250 million in revenue. SpaceX was generating an estimated $8 billion in profit on $15 billion in revenue and needed an AI narrative to command the valuation it was targeting for its IPO.
What SpaceX has done, regardless of how the orbital AI vision ultimately plays out, is walk into a public market as something no company has been before: a rocket manufacturer, satellite internet provider, AI software company, social media platform, and supercomputer operator under one ticker. Whether that combination is worth $2 trillion depends entirely on which of those businesses you believe in most.
News
Tesla flexes how it will help the blind with Cybercab
Tesla brought its innovative Cybercab robotaxi to the National Federation of the Blind (NFB) Annual Convention in Austin, Texas, on July 3 at the JW Marriott Austin.
The hands-on demonstration highlighted the vehicle’s thoughtful design for blind and visually impaired users, underscoring Tesla’s commitment to inclusive autonomous mobility. Attendees, many using white canes or accompanied by service dogs, experienced the steering-wheel-free Cybercab firsthand.
Cybercab at the National Federation of the Blind’s Annual Convention in Austin for a hands-on experience of its accessibility features for blind or visually impaired customers⁰⁰For example:⁰– Braille lettering on physical controls
– Space for service animals & assistive… pic.twitter.com/8wrJcDHkw7— Tesla Robotaxi (@robotaxi) July 6, 2026
The showcase emphasized practical features tailored to the needs of the blind community. Braille lettering appears on physical controls, including door releases and emergency buttons, allowing users to navigate interfaces independently through touch. Generous interior space accommodates service animals and assistive devices such as canes, guide dogs, or mobility aids without compromising comfort.
Wheelchair-height seating facilitates easier transfers for users with additional mobility challenges. Photos from the event captured blind attendees approaching the vehicle confidently, service dogs relaxing inside, and hands exploring Braille-equipped handles.
Tesla Robotaxi’s official account detailed these elements, noting the Cybercab’s focus on accessibility, especially noting the Braille lettering and additional space for service animals.
How Tesla Will Transform Mobility for the Blind
Autonomous vehicles like the Cybercab promise revolutionary independence for the roughly 2.2 million visually impaired Americans. Traditional barriers—reliance on sighted drivers, costly paratransit, or limited public transit—often restrict spontaneous travel. Tesla Full Self-Driving aims to eliminate the need for a human operator, enabling on-demand, door-to-door rides via simple app hailing with voice guidance.
Users gain freedom to work, socialize, shop, or attend events anytime without scheduling hassles or safety concerns. This reduces isolation, boosts employment opportunities, and enhances quality of life, turning mobility from a dependency into true personal autonomy.
The NFB demonstration not only gathered valuable feedback but also generated excitement about a future where technology levels the playing field. By prioritizing inclusive design, Tesla advances a vision of transportation that serves everyone, potentially reshaping daily life for blind individuals and setting a standard for the autonomous industry.
As Cybercab deployment scales, these accessibility innovations could mark a significant step toward equitable mobility.
Investor's Corner
Tesla challenges startups to score a gig inside its most advanced European factory
Tesla is challenging startups to bring their best battery tech directly to Gigafactory Berlin.
Tesla has issued an open challenge to startups across Europe, inviting them to bring their best battery technology directly to the floor of Gigafactory Berlin. The program, called the JUNI x Tesla Battery Cell Giga Challenge, opened applications this month with a deadline of July 24, 2026, and is targeting startups with solutions that can make battery cell manufacturing faster, cheaper, safer, and more scalable at an industrial level.
The timing of the challenge is directly tied to Tesla’s most aggressive European battery investment yet. On May 12, 2026, Giga Berlin plant manager André Thierig announced a $250 million investment to scale the factory’s annual 4680 cell production capacity from 8 GWh to 18 GWh, more than doubling the previous target set just months earlier in December 2025. Thierig confirmed the expansion on X, saying the investment “will enable 18 GWh of annual 4680 cell production and create more than 1,500 new jobs.” Combined with a previously announced battery investment at the Grunheide site now approaches $1.2 billion.
Today, we announced a $ 250m investment for our Giga Berlin Cell factory. This will enable 18GWh of annual 4680 cell production and create more than 1500 new jobs. Good news during challenging times for the German industry. pic.twitter.com/ou4SWMfWh9
— André Thierig (@AndrThie) May 12, 2026
The challenge is looking specifically for startups with proven solutions across five categories: materials, equipment, operations, automation, and artificial intelligence. Applications are screened directly by Tesla’s cell manufacturing team in Grunheide, and the strongest submissions move through technical discussions, a pitch day in front of Tesla stakeholders, and potentially a paid pilot project with the cell team. Tesla is not looking for ideas at concept stage. The program requires applicants to demonstrate working prototypes, test data, or prior pilots before being considered.
The historical context matters here. Elon Musk first announced plans for what he called the world’s largest battery cell production facility alongside the Giga Berlin car factory back in 2020, targeting up to 250 GWh of annual capacity. Those plans were shelved in 2022 when Tesla shifted its battery investment focus to the United States to take advantage of Inflation Reduction Act incentives. The revival of cell production at Giga Berlin, now backed by over $1 billion in committed capital, represents a return to an ambition that was set aside for three years. As Teslarati has reported, the 4680 format is central to Tesla’s long-term cost reduction strategy across vehicles, energy storage, including the Tesla Semi and Cybercab.
By opening the challenge to outside startups, Tesla is acknowledging that reaching 18 GWh at Grunheide will require technology it does not currently have in-house, and it is willing to pay for the right solutions. For a startup in the battery supply chain, a paid pilot with Tesla’s European cell team is as close to a direct commercial path as the industry offers.